Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study-Reference-Cited by-同舟云学术

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Published:2017-10-23 Issue:3 Volume:167 Page:671-686
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Dirix Luc Y.^ORCID,Takacs Istvan,Jerusalem Guy,Nikolinakos Petros,Arkenau Hendrik-Tobias,Forero-Torres Andres,Boccia Ralph,Lippman Marc E.,Somer Robert,Smakal Martin,Emens Leisha A.,Hrinczenko Borys,Edenfield William,Gurtler Jayne,von Heydebreck Anja,Grote Hans Juergen,Chin Kevin,Hamilton Erika P.

Funder

Merck KGaA

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4537-5/fulltext.html

Reference34 articles.

1. O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29

2. National Cancer Institute (2016) SEER cancer stat facts: female breast cancer. National Cancer Institute, Bethesda, p 2016

3. National Comprehensive Cancer Network (V2 2017) (2017) NCCN clinical practice guidelines in oncology: breast cancer. National Comprehensive Cancer Network, Orlando

4. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434

5. Anders CK, Abramson V, Tan T et al (2016) The evolution of triple-negative breast cancer: from biology to novel therapeutics. Am Soc Clin Oncol Educ Book 35:34–42

Cited by 568 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving immunotherapeutic solutions for triple-negative breast carcinoma;Cancer Treatment Reviews;2024-11

2. PD-L1 expression and tumor-infiltrating lymphocytes: Correlations and prognostic values in Chinese triple-negative breast cancer patients with different molecular subtyping;Pathology - Research and Practice;2024-10

3. Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment;Cancer Drug Resistance;2024-09-13

4. Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden;Journal of Gastrointestinal Cancer;2024-09-10

5. Exceptional response to pembrolizumab in HER2-positive gallbladder carcinoma with high tumor mutational burden;2024-09-09